GenSight Biologics S.A.
GSGTF
$0.19
-$0.05-20.79%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 207.60K | 916.90K | 1.62M | 1.25M | 868.70K |
| Total Other Revenue | 816.00K | 1.01M | 1.22M | 1.24M | 1.27M |
| Total Revenue | 1.02M | 1.93M | 2.84M | 2.49M | 2.14M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 1.02M | 1.93M | 2.84M | 2.49M | 2.14M |
| SG&A Expenses | 6.29M | 6.37M | 6.57M | 7.80M | 9.01M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.56M | 18.59M | 19.95M | 21.90M | 23.78M |
| Operating Income | -16.53M | -16.66M | -17.11M | -19.41M | -21.64M |
| Income Before Tax | -16.44M | -15.62M | -15.13M | -18.46M | -21.75M |
| Income Tax Expenses | 7.50K | 15.30K | 22.70K | 13.10K | 3.20K |
| Earnings from Continuing Operations | -16.45 | -15.64 | -15.15 | -18.48 | -21.76 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -16.45M | -15.64M | -15.15M | -18.48M | -21.76M |
| EBIT | -16.53M | -16.66M | -17.11M | -19.41M | -21.64M |
| EBITDA | -16.34M | -16.21M | -16.38M | -17.92M | -19.38M |
| EPS Basic | -0.14 | -0.15 | -0.16 | -0.27 | -0.38 |
| Normalized Basic EPS | -0.09 | -0.09 | -0.10 | -0.17 | -0.24 |
| EPS Diluted | -0.14 | -0.15 | -0.16 | -0.27 | -0.38 |
| Normalized Diluted EPS | -0.09 | -0.09 | -0.10 | -0.17 | -0.24 |
| Average Basic Shares Outstanding | 474.07M | 428.54M | 383.02M | 324.82M | 266.62M |
| Average Diluted Shares Outstanding | 474.07M | 428.54M | 383.02M | 324.82M | 266.62M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |